Skip to search formSkip to main contentSkip to account menu

NKTR-118

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

naloxegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The role of naloxegol in the management of opioid-induced bowel dysfunction
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD… 
2015
2015
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study
This randomized, double‐blind, placebo‐controlled, ascending‐dose, crossover study evaluated single oral doses of naloxegol (NKTR… 
2015
2015
Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol
Opioid‐induced constipation (OIC) is the most common and often a treatment‐limiting adverse event (AE) of opioid therapy for… 
Highly Cited
2013
Highly Cited
2013
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation
2013
2013
New treatment possibilities for opioid-induced bowel dysfunction
Review
2011
Review
2011
Novel opioid antagonists for opioid-induced bowel dysfunction
Introduction: Adverse effects frequently limit the therapeutic benefits of opioid analgesics. Gastrointestinal adverse effects… 
2009
2009
NKTR-118 Significantly Reverses Opioid-Induced Constipation
NKTR-118, a novel PEGylated naloxol conjugate, is an oral, once daily investigational agent in development for treatment of… 
2009
2009
Efficacy, Safety and Pharmacokinetics of Oral NKTR-118 in Patients with Opioid-Induced Constipation: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 Study: 466
2009
2009
AstraZeneca Inks Deal with Nektar
AstraZeneca has signed a licensing deal with Nektar Therapeutics to develop and market the latter’s two drugs, NKTR-118 and NKTR… 
2008
2008
(210) Results from a phase I, double-blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetics of oral doses of NKTR-118
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)